Namyang Dairy saw a surge in its shares after claiming its Bulgaris yogurt variants can help lower the risk of COVID-19 infection. The company's day trading on Wednesday, April 14, reportedly increased.
As per The Korea Herald, Namyang Dairy’s shares once shot up by 28.68% to KRW489,000 or around $437.39 in the early morning trading. It was added that within 20 minutes after the opening bell, the company’s preferred stocks also surge by the daily allowable limit of 29.78% to reach KRW231,000.
Prior to Wednesday’s results, it was reported that the firm’s shares went up 7.19% and 6.71% on Friday and Monday, respectively. It then increased again by 8.57% on Tuesday, and this shows that Namyang Dairy’s shares have been on the rise since last weekend and continued this week.
Namyang’s COVID-19 claim
Observers are saying that the company’s surge in shares may be due to its claims that its Bulgaris yogurt lineup can help reduce the risk of getting COVID-19. Some market insiders also think that some investors may have also used information that caused the hike in the recent stock tradings.
At any rate, what triggered the sudden increase in shares of Namyang Dairy was the statement given by the company during a news conference in Seoul.
“We’re the first firm in the country that has discovered fermented dairy products are effective in preventing influenza and COVID-19 viruses,” Namyang’s chief of antiviral immune research center, Park Jong Su, said at that time. “Our experiments showed that Bulgaris helped remove the Influenza A (H1N1) virus at a 99.999 percent rate of success, and the COVID-19 at a 77.8 percent success rate.”
He added that the test of the yogurt’s effectiveness in fighting coronavirus was done using the lung cells of a monkey. As a result of this claim, people reportedly rushed out to purchase Namyang Dairy’s Bulgaris yogurts in stores.
Statement from S. Korea’s health officials
After the announcement from Namyang, the public health authorities released a statement. The agency expressed its concern over the claims.
“The latest research result has not proved to be effective in eliminating those viruses in the human body,” the Korea Disease Control and Prevention Agency stated. “Therefore, it is hard to say whether it can serve as an actual prevention or treatment measure for (the viruses).”


China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Yen Slides as Japan Election Boosts Fiscal Stimulus Expectations
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Instagram Outage Disrupts Thousands of U.S. Users
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 



